HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition.

AbstractUNLABELLED:
Recent whole genome melanoma sequencing studies have identified recurrent mutations in the gene encoding the catalytic subunit of serine/threonine phosphatase 6 (PPP6C/PP6C). However, the biochemical, functional, and clinical ramifications of these mutations are unknown. Sequencing PP6C from patients with melanoma (233 primary and 77 metastatic specimens) with extended prospective clinical outcome revealed a large number of hotspot mutations in patients with both primary and metastatic melanoma. Despite minimal association between stage and presence of PP6C mutations in patients with primary melanoma, a subpopulation of cells within each tumor did contain PP6C mutations, suggesting PP6C mutation is an early, but non-tumor-initiating event in melanoma. Among patients with primary melanoma with PP6C mutations, patients with stop mutations had significantly shorter recurrence-free survival compared with patients without stop mutations. In addition, PP6C mutations were independent of commonly observed BRAF and NRAS mutations. Biochemically, PP6C mutations could be classified as those that interact with PP6C regulatory subunits and those that do not. Mutations that did not bind to PP6C regulatory subunits were associated with increased phosphorylation of Aurora kinase, a PP6C substrate, and mitotic defects. However, both classes of PP6C mutations led to increased sensitivity to Aurora kinase inhibition. Together, these data support for the first time that PP6C mutations are molecularly, biochemically, and clinically heterogeneous.
IMPLICATIONS:
PP6C mutations have distinct functional and clinical consequences in melanoma, and confer sensitivity to Aurora A kinase inhibitors.
AuthorsHeidi L Gold, Jordan Wengrod, Eleazar Vega-Saenz de Miera, Ding Wang, Nathaniel Fleming, Lisa Sikkema, Tomas Kirchhoff, Tsivia Hochman, Judith D Goldberg, Iman Osman, Lawrence B Gardner
JournalMolecular cancer research : MCR (Mol Cancer Res) Vol. 12 Issue 3 Pg. 433-9 (Mar 2014) ISSN: 1557-3125 [Electronic] United States
PMID24336958 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Protein Subunits
  • Aurora Kinases
  • Phosphoprotein Phosphatases
  • protein phosphatase 6
Topics
  • Aurora Kinases (antagonists & inhibitors, metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Male
  • Melanoma (drug therapy, enzymology, genetics, pathology)
  • Mutation
  • Neoplasm Staging
  • Phosphoprotein Phosphatases (antagonists & inhibitors, genetics, metabolism)
  • Prognosis
  • Protein Kinase Inhibitors
  • Protein Subunits
  • Skin Neoplasms (drug therapy, enzymology, genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: